Combination Therapy for Non-alcoholic Steatohepatitis: Rationale, Opportunities and Challenges

Overview

Journal Gut

Specialty Gastroenterology

Date 2020 May 9

PMID 32381514

Citations 85

Authors

Jean-Francois Dufour

Cyrielle Caussy

Rohit Loomba

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.

Citing Articles

Metabolic dysfunction-associated steatotic liver disease in adults.

Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H Nat Rev Dis Primers. 2025; 11(1):14.

PMID: 40050362 DOI: 10.1038/s41572-025-00599-1.

Simulations Reveal Unique Roles for the FXR Hinge in the FXR-RXR Nuclear Receptor Heterodimer.

Yu T, Biswas A, Dube N, Okafor C ACS Bio Med Chem Au. 2025; 5(1):194-203.

PMID: 39990948 PMC: 11843329. DOI: 10.1021/acsbiomedchemau.4c00105.

Potential therapeutic strategies for MASH: from preclinical to clinical development.

Xie Z, Li Y, Cheng L, Huang Y, Rao W, Shi H Life Metab. 2025; 3(5):loae029.

PMID: 39872142 PMC: 11749562. DOI: 10.1093/lifemeta/loae029.

Emerging role of exosomes during the pathogenesis of viral hepatitis, non-alcoholic steatohepatitis and alcoholic hepatitis.

Shi C, Hu S, Liu S, Jia X, Feng Y Hum Cell. 2024; 38(1):26.

PMID: 39630211 DOI: 10.1007/s13577-024-01158-8.

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).

Do A, Zahrawi F, Mehal W Nat Rev Drug Discov. 2024; 24(3):171-189.

PMID: 39609545 DOI: 10.1038/s41573-024-01084-2.

References

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

Williams C, Stengel J, Asike M, Torres D, Shaw J, Contreras M . Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2010; 140(1):124-31. DOI: 10.1053/j.gastro.2010.09.038. View

Li Y, Zhu S, Li B, Shao X, Liu X, Liu A . Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetes. Int Urol Nephrol. 2014; 46(9):1785-91. DOI: 10.1007/s11255-014-0796-9. View

Neuschwander-Tetri B, Clark J, Bass N, Van Natta M, Unalp-Arida A, Tonascia J . Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010; 52(3):913-24. PMC: 3070295. DOI: 10.1002/hep.23784. View

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

Davies M, Pieber T, Hartoft-Nielsen M, Hansen O, Jabbour S, Rosenstock J . Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017; 318(15):1460-1470. PMC: 5817971. DOI: 10.1001/jama.2017.14752. View

Harrison S, Bashir M, Guy C, Zhou R, Moylan C, Frias J . Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019; 394(10213):2012-2024. DOI: 10.1016/S0140-6736(19)32517-6. View

Thomas M, Cherney D . The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018; 61(10):2098-2107. DOI: 10.1007/s00125-018-4669-0. View

Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz E, Bennett M . GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018; 155(5):1463-1473.e6. PMC: 6318218. DOI: 10.1053/j.gastro.2018.07.027. View

10.

Musso G, Cassader M, Paschetta E, Gambino R . Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017; 177(5):633-640. PMC: 5470366. DOI: 10.1001/jamainternmed.2016.9607. View

11.

Younossi Z, Gramlich T, Matteoni C, Boparai N, McCullough A . Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004; 2(3):262-5. DOI: 10.1016/s1542-3565(04)00014-x. View

12.

Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F . Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011; 54(3):837-45. DOI: 10.1002/hep.24483. View

13.

Petit J, Cercueil J, Loffroy R, Denimal D, Bouillet B, Fourmont C . Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study. J Clin Endocrinol Metab. 2016; 102(2):407-415. DOI: 10.1210/jc.2016-2775. View

14.

Doycheva I, Cui J, Nguyen P, Costa E, Hooker J, Hofflich H . Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2015; 43(1):83-95. PMC: 4673036. DOI: 10.1111/apt.13405. View

15.

Zinman B, Lachin J, Inzucchi S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016; 374(11):1094. DOI: 10.1056/NEJMc1600827. View

16.

Traussnigg S, Schattenberg J, Demir M, Wiegand J, Geier A, Teuber G . Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. Lancet Gastroenterol Hepatol. 2019; 4(10):781-793. DOI: 10.1016/S2468-1253(19)30184-0. View

17.

Younossi Z, Ratziu V, Loomba R, Rinella M, Anstee Q, Goodman Z . Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019; 394(10215):2184-2196. DOI: 10.1016/S0140-6736(19)33041-7. View

18.

Ratziu V, Sanyal A, Harrison S, Wong V, Francque S, Goodman Z . Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology. 2020; 72(3):892-905. DOI: 10.1002/hep.31108. View

19.

Hernandez A, Green J, Janmohamed S, DAgostino Sr R, Granger C, Jones N . Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392(10157):1519-1529. DOI: 10.1016/S0140-6736(18)32261-X. View

20.

Harrison S, Alkhouri N, Davison B, Sanyal A, Edwards C, Colca J . Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. J Hepatol. 2019; 72(4):613-626. DOI: 10.1016/j.jhep.2019.10.023. View